Literature DB >> 6107910

Somatostatin: an endogenous peptide in the toad urinary bladder inhibits vasopressin-stimulated water flow.

J N Forrest, S Reichlin, D B Goodman.   

Abstract

Somatostatin (somatotropin release-inhibiting factor; SRIF) is a tetradecapeptide present in brain, pancreas, gastrointestinal tract, and thyroid that inhibits the secretion or action of several hormones in these tissues. We observed that the toad urinary bladder contains concentrations of endogenous somatostatin (8.0 pg/micrograms of protein) comparable to those found in the mammalian pancreas and gastrointestinal tract. To determine if somatostatin directly alter the action of vasopressinn we studied the effects of this polypeptide on vasopressin-stimulated transport processes in the toad urinary bladder in vitro. Somatostatin produced a dose-dependent, reversible inhibition of vasopressin-stimulated osmotic water flow; it inhibited theophylline-stimulated osmotic water flow but not the water flow stimulated by 8-p-chlorophenylthioadenosine 3',5'-cyclic monophosphate. These data are consistent with an inhibition of both basal and hormone-stimulated adenylate cyclase. Vasopressin-stimulated short circuit current was not inhibited by somatostatin. These studies provide direct evidence for an effect of somatostatin on hormone-modulated epithelial transport in tissues other than the gastrointestinal tract. We propose that endogenous somatostatin may function as a local regulator of the cellular action of vasopressin on osmotic water flow.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6107910      PMCID: PMC349974          DOI: 10.1073/pnas.77.8.4984

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  35 in total

1.  Effects of somatostatin on pancreatic exocrine function. Interaction with secretin.

Authors:  P Robberecht; M Deschodt-Lanckman; P De Neef; J Christophe
Journal:  Biochem Biophys Res Commun       Date:  1975-11-03       Impact factor: 3.575

2.  Immunohistochemical evidence for the localization of somatostatin--like immunoreactivity in a cell population of the pancreatic islets.

Authors:  R Luft; S Efendic; T Hökfelt; O Johansson; A Arimura
Journal:  Med Biol       Date:  1974-12

3.  Reversal of somatostatin inhibition of insulin secretion by calcium.

Authors:  D L Curry; L L Bennett
Journal:  Biochem Biophys Res Commun       Date:  1974-10-08       Impact factor: 3.575

4.  Inhibition of adenosine 3',5'-monophosphate accumulation in anterior pituitary gland in vitro by growth hormone-release inhibiting hormone.

Authors:  P Borgeat; F Labrie; J Drouin; A Bélanger; H Immer; K Sestanj; V Nelson; M Götz; A V Schally; D H Coy; E J Coy
Journal:  Biochem Biophys Res Commun       Date:  1974-02-27       Impact factor: 3.575

5.  The effect of aldosterone on the accumulation of adenosine 3':5'-cyclic monophosphate in toad bladder epithelial cells in response to vasopressin and theophylline.

Authors:  J S Stoff; J S Handler; J Orloff
Journal:  Proc Natl Acad Sci U S A       Date:  1972-04       Impact factor: 11.205

6.  Effect of prostaglandin E1 on sodium transport and osmotic water flow in the toad bladder.

Authors:  L C Lipson; G W Sharp
Journal:  Am J Physiol       Date:  1971-04

7.  Effects of growth-hormone release-inhibiting hormone on circulating glucagon, insulin, and growth hormone in normal, diabetic, acromegalic, and hypopituitary patients.

Authors:  C H Mortimer; W M Tunbridge; D Carr; L Yeomans; T Lind; D H Coy; S R Bloom; A Kastin; C N Mallinson; G M Besser; A V Schally; R Hall
Journal:  Lancet       Date:  1974-04-20       Impact factor: 79.321

8.  Effects of somatostatin on the secretion of thyrotropin and prolactin.

Authors:  W Vale; C Rivier; P Brazeau; R Guillemin
Journal:  Endocrinology       Date:  1974-10       Impact factor: 4.736

9.  Effect of prostaglandins and their inhibitors on osmotic water flow in the toad bladder.

Authors:  A Ozer; G W Sharp
Journal:  Am J Physiol       Date:  1972-03

10.  Inhibition of glucagon and insulin secretion by somatostatin in the rat pancreas perfused in situ.

Authors:  D G Johnson; J W Ensinck; D Koerker; J Palmer; C J Goodner
Journal:  Endocrinology       Date:  1975-02       Impact factor: 4.736

View more
  3 in total

1.  Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.

Authors:  Marie C Hogan; Tetyana V Masyuk; Linda J Page; Vickie J Kubly; Eric J Bergstralh; Xujian Li; Bohyun Kim; Bernard F King; James Glockner; David R Holmes; Sandro Rossetti; Peter C Harris; Nicholas F LaRusso; Vicente E Torres
Journal:  J Am Soc Nephrol       Date:  2010-04-29       Impact factor: 10.121

Review 2.  Strategies targeting cAMP signaling in the treatment of polycystic kidney disease.

Authors:  Vicente E Torres; Peter C Harris
Journal:  J Am Soc Nephrol       Date:  2013-12-12       Impact factor: 10.121

Review 3.  Rare cystic liver lesions: a diagnostic and managing challenge.

Authors:  Andreas Bakoyiannis; Spiros Delis; Charina Triantopoulou; Christos Dervenis
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.